Hyperkalemia treatment standard.

This article focuses on the clinical management of hyperkalemia, an electrolyte disorder characterized by elevated plasma potassium (K⁺) levels, distinguishing between acute and chronic forms. Acute hyperkalemia develops rapidly and can cause life-threatening cardiac complications, requiring immediate treatment to stabilize the cardiac membrane, promote cellular K⁺ uptake, and reduce total body K⁺. Chronic hyperkalemia develops gradually, often linked to kidney dysfunction and medications affecting the renin–angiotensin–aldosterone system (RAAS), and is managed by reviewing medications, ensuring effective diuretic use, correcting metabolic acidosis, and employing potassium-binding drugs and sodium–glucose cotransporter 2 (SGLT2) inhibitors. The article emphasizes maintaining RAAS inhibitors when possible due to their cardiovascular benefits and advocates for nuanced dietary potassium restriction, focusing on reducing highly bioavailable potassium from processed foods rather than broadly limiting fruits and vegetables.